What is the therapeutic effect of Glecaprevir/pibrentasvir tablets?

Glecaprevir/pibrentasvir is a drug used to treat hepatitis C virus (HCV). There are six genotypes of the hepatitis C virus, and glecaprevir and pibrentasvir tablets have been shown to be effective in clearing the virus from the blood of all genotypes.

In multiple studies, eight major clinical trials involving more than 2,300 adult patients have shown that glecaprevir and pibrentasvir tablets are extremely effective. Among them, for genotype 1 patients without cirrhosis, 99% of the virus test results were negative after 8 weeks of treatment; while for genotype 1 patients with cirrhosis, 97% also showed negative results after 8 or 12 weeks. This negative result indicates that the hepatitis C virus cannot be detected in the body. Similar effects were seen in other genotypes, particularly those with genotypes 2 and 4 to 6. For genotype 3, although its effectiveness is slightly lower, 95% of patients still become virus negative after treatment.

In addition, studies on children further verified the effectiveness of glecaprevir and pibrentasvir tablets. In a study of 47 children aged 12 to 18 years with genotypes 1 to 4 and without cirrhosis, all patients who received 12 weeks of treatment tested negative after treatment. Meanwhile, a study of children aged 3 to 11 years without cirrhosis and with HCV genotypes 1-4 showed that of the 62 participants who received the final recommended dose, they tested negative for the virus after 8 weeks if they had not received other previous treatments, and after 12 to 16 weeks if they had been treated with interferon.

These research results show that the drug metabolism of glecaprevir and pibrentasvir tablets is similar in children and adults, showing good safety and efficacy. Based on available adult data, it is expected that glecaprevir and pibrentasvir tablets will also be suitable for pediatric patients with genotypes 5 and 6. Therefore, glecaprevir and pibrentasvir tablets not only provide an effective treatment option for adult patients with hepatitis C, but also bring new hope to pediatric patients.

Reference materials:https://www.mavyret.com/